BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37483851)

  • 1. Oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer.
    Şendoğan F; Turan T; Keser F; Hancilar T; Atis G; Yildirim A
    Cent European J Urol; 2023; 76(2):109-115. PubMed ID: 37483851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.
    Vogel MME; Kessel KA; Schiller K; Devecka M; Gschwend JE; Weichert W; Wilkens JJ; Combs SE
    Radiat Oncol; 2019 Nov; 14(1):198. PubMed ID: 31711524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.
    Taylor N; Kelly JF; Kuban DA; Babaian RJ; Pisters LL; Pollack A
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):755-63. PubMed ID: 12788182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
    Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
    Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
    Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
    Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
    Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
    Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
    Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
    Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.
    Hervás A; Gómez-Caamaño A; Casaña M; Gómez-Iturriaga A; Pastor J; Jove J; Mengual JL; Gónzalez-San Segundo C; Muñoz J
    Clin Transl Oncol; 2018 Feb; 20(2):193-200. PubMed ID: 28667448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy.
    Tseng CS; Wang YJ; Chen CH; Wang SM; Huang KH; Chow PM; Pu YS; Huang CY; Cheng JC
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adjuvant vs. salvage radiotherapy after radical prostatectomy].
    Bartkowiak D; Schrader AJ; Wiegel T
    Aktuelle Urol; 2015 Jan; 46(1):52-8. PubMed ID: 25658231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.